PHARMA TECHNOLOGY
ActiveSummary
PHARMA TECHNOLOGY has been active since 1991 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €16.3m and a net result of €3.8m. Equity remains stable across the filed financial years (±2.3% per year). Its solvency ranks better than 70% of 143 sector peers (NACE 32, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Directors
Board 2
Day-to-day management 1
Permanent representatives 2
Not every act has been read: a resignation may still be missing
Mandate history
- Board
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| ADFINITIS SRL |
|
| NEXTGEN INVEST SRL |
|
| PHARMA FLEX SA |
|
| Claire BECKER |
|
| DOLLINGER Martial Arthur Charles Benoit |
|
Owners and capital
Owners
2 ownersChain of control
- AdFinitis
- PHARMA FLEX
- PHARMA TECHNOLOGY
Highest known parent: AdFinitis. The sources do not say who stands above it.
Owners 2
- PHARMA FLEXparent99.96%
- Martial Dollingernatural personSourceown accounts 20250.04%
Own shares 99.96% Source own accounts 2025
According to the 2025 annual accounts of PHARMA TECHNOLOGY and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.